Concepta PLC Chinese Manufacturing Agreement Signed (7527K)
26 September 2016 - 4:00PM
UK Regulatory
TIDMCPT
RNS Number : 7527K
Concepta PLC
26 September 2016
Concepta plc ("Concepta" or the "Company")
Chinese Manufacturing Agreement Signed with Shijiazhuang
Huanzhong Biotech Limited
Concepta plc (AIM:CPT), the UK healthcare company targeting the
personalised mobile health market with a primary focus on women's
fertility, announces that it has signed a Manufacturing Agreement
('the Agreement') with Shijiazhuang Huanzhong Biotech Limited ('HZ
Biotech'), a leading Chinese manufacturer with operations in
Shijiazhuang, to assemble and package Concepta's 'My Lotus'
fertility product. This Agreement is in line with the Company's
strategy as it builds towards the launch of its My Lotus product
for unexplained infertility* into China in H2 2016.
Under the terms of the Agreement, HZ Biotech will exclusively
assemble and package Concepta produced components (including bulk
tests and electronic meters), to produce Concepta's My Lotus
product to specification for the Chinese market. HZ will utilise
its manufacturing site and processes, adhering to locally
applicable laws and Chinese regulatory requirements. In addition to
assembling the final My Lotus product, HZ Biotech will be the sole
purchaser of Concepta's My Lotus product and help facilitate its
launch to the Chinese market and include post-market surveillance.
Concepta will also look to work with a network of distributors in
China to help achieve maximum market penetration in China and will
update the market on these developments in due course.
Concepta's MyLotus is the only consumer product which allows
both quantitative and qualitative measurements of a woman's
personal hCG and LH hormone levels in an easy to use home test to
facilitate higher conception rates and early diagnosis of any
fertility problems. Competitor products currently only allow
qualitative measurement and are based on the 'average woman'.
Commenting on the Agreement, Erik Henau, Concepta CEO said: "I
am delighted to announce this agreement with leading Chinese
manufacturer HZ Biotech, which marks a significant step for
Concepta towards the launch of our 'My Lotus' fertility product
into China in 2016. With regulatory approvals already in place in
China, the Chinese market represents a highly attractive initial
launch market for Concepta. An estimated 4 million women in China
each year discover that they have unexplained infertility. The
sheer scale of the target market, combined with a growing Chinese
middle class for whom our My Lotus product is affordable and recent
regulatory changes regarding the one-child policy, all create the
conditions for an exceptional market opportunity. As such annual
revenue potential for this target market is expected to be worth
GBP250m per annum.
"We look forward to updating the market on our progress with HZ
Biotech as we roll out our flagship fertility product in our first
international market with the UK and Europe targeted for 2017."
ENDS
Enquiries:
The Company
Adam Reynolds, Chairman
Tel: +44 (0) 7785 908158
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin/Mark Brady
Tel: +44 (0)20 368 3550
Beaufort Securities Limited (Broker)
Jon Belliss
Tel: +44 (0)20 7382 8300
Yellow Jersey PR Limited (Financial PR)
Felicity Winkles/ Joe Burgess/ Josh Cole
Tel: +44 (0) 7748 843 871
About Concepta Plc:
Concepta plc is a pioneering UK healthcare company that has
developed a proprietary platform and products targeted at the
personalised mobile health market with a primary focus on women's
fertility and specifically unexplained infertility*.
Founded in 2013, Concepta has developed a revolutionary flagship
product 'MyLotus' for home self-testing that helps women with
unexplained infertility to conceive.
MyLotus is the only consumer product which allows both
quantitative and qualitative measurements of measurement of a
woman's personal hCG and LH hormone levels in an easy to use home
test to facilitate higher conception rates and early diagnosis of
any fertility problems. Competitor products currently only allow
qualitative measurement and are based on the 'average woman'.
Concepta has a defined route to market for its new 'My Lotus'
product with Regulatory approvals for launch in China in place for
2016 and CE-Marking for UK and Europe to follow in 2017 where the
revenue potential of the Chinese and EU infertility market is worth
c.GBP600m per annum for the company.
*Unexplained infertility refers to women that have been unable
to conceive after 6 months of trying. This highly motivated target
group of consumers won't typically be offered medical intervention
until 12 months of unsuccessfully trying, with IVF not offered
until two years. Research indicates couples start to take positive
action ahead of this time and there is little medical support to
help them do so.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRLAMRTMBTTBJF
(END) Dow Jones Newswires
September 26, 2016 02:00 ET (06:00 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024